Clinical Trials Browser

Interventional × tazemetostat × Head & Neck × Clear all

NCT04624113 2024-02-21

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck